Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Blue Origin safely launches wheelchair user to space and back - 2An 'explosion' of solo-agers are struggling with rising costs and little support: 'I'm flying without a net'
- 3vote in favor of Your #1 kind of climate
- 4The Best Design Bloggers for Style Motivation
- 5Mussolini's summer villa on Adriatic coast sold for €1.2 million
- 21 Incredibly Interesting Contemplations To Observe Consistently
- Traveling Alone: An Excursion of Self-Disclosure
- New study measures titanium in Apollo rock to uncover Moon’s early chemistry
- In a scientific first, biologists recorded a wild wolf potentially using tools
- 7 Extraordinary Efficiency Applications for Experts
- Step by step instructions to Protect Your Retirement with Senior Protection.
- Hamas demanded displaced Gazans pay rent on beach tents amid torrential downpour, IDF reveals
- Amazon sued over 'punitive' handling of employee absences
- How C-reactive protein outpaced ‘bad’ cholesterol as leading heart disease risk marker
